Altimmune, Inc.

70 articles with Altimmune, Inc.

• Altimmune to Present Pemvidutide Clinical Data at Upcoming NASH-TAG Conference January 8, 2022

  1/3/2022

  Altimmune, Inc. today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company’s novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD).

• Altimmune Appoints Richard Eisenstadt as Chief Financial Officer

  12/13/2021

  Altimmune, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases, announced the appointment of Richard Eisenstadt as Chief Financial Officer, effective December 31, 2021.

• Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 13, 2021

  12/13/2021

  Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that the Compensation Committee of its Board of Directors granted equity awards under Altimmune’s 2018 Inducement Grant Plan, as a material inducement to employ Richard Eisenstadt as Altimmune’s Chief Financial Officer effective December 31, 2021.

• Altimmune to Present at Upcoming Investor and Scientific Conferences - Nov 22, 2021

  11/22/2021

  Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will be presenting virtually at the following conferences.

• Altimmune to Present at Upcoming Investor Conferences - Nov 10, 2021

  11/10/2021

  Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the Company’s management team will be presenting virtually at the following investor conferences in November 2021.

• Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

  11/9/2021

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and nine-months ending September 30, 2021 and provided a corporate update.

• Altimmune to Announce Third Quarter 2021 Financial Results on November 10, 2021

  11/3/2021

  Altimmune, Inc. today announced that it will report its third quarter 2021 financial results on Wednesday, November 10, 2021.

• 

  Clinical Catch-Up: October 4-8

  10/11/2021

  Another busy week for clinical trial news. Here’s a look.

• Altimmune to Present at Upcoming H.C. Wainwright Investor Conferences October 12-13, 2021

  10/6/2021

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will be presenting virtually at the following H.C. Wainwright Investor Conferences.

• 

  Clinical Catch-Up: September 27-October 1

  10/4/2021

  It was a busy week for clinical trial news. Here’s a look.

• Altimmune Announces Initiation of 12-week Phase 1b Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease

  10/4/2021

  First patient has been enrolled in 12-week non-alcoholic fatty liver disease (NAFLD) study

• Altimmune to Host Key Opinion Leader Call with Dr. Stephen Harrison on Pemvidutide Phase 1 Clinical Trial Results on September 30, 2021

  9/29/2021

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will host a Key Opinion Leader (KOL) call on its 12-week Phase 1 clinical trial of pemvidutide (proposed INN, formerly known as ALT-801) in overweight and obese subjects on Thursday, September 30, 2021 at 9:00 am EST.

• Altimmune Announces Positive Results From 12-week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers

  9/28/2021

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive results from a 12-week, Phase 1 trial of pemvidutide (proposed INN, formerly known as ALT-801), an investigational glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist.

• Altimmune to Announce 12-Week Data From ALT-801 Phase 1 Trial on September 28, 2021

  9/27/2021

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report the results from its 12-week Phase 1 clinical trial of ALT-801 in overweight and obese subjects in a pre-market press release and webcast to be held on Tuesday, September 28, 2021.

• 

  Bharat's Intranasal Vaccine Speeds into Phase II on Heels of Strong Data

  9/10/2021

  This marks the second vaccine against the novel coronavirus developed by the India-based company and brings a significant milestone for intranasal formulations.

• Altimmune to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

  9/7/2021

  Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.

• 

  Hoping to Change the Game, Bharat's Intranasal Vaccine Moves Forward

  8/16/2021

  By administering a vaccine directly into the nasal cavity, the mucus membranes of the nose and throat would provide better protection than the intramuscular alone. 

• Altimmune Announces Second Quarter 2021 Financial Results and Provides a Corporate Update

  8/10/2021

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three- and six-months ending June 30, 2021 and provided a corporate update.

• Altimmune to Announce Second Quarter 2021 Financial Results on August 11, 2021

  8/4/2021

  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2021 financial results on Wednesday, August 11, 2021.

• 

  Clinical Catch-Up: June 28-July 2

  7/6/2021

  It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look.